The presentation is a forward-looking pipeline update without hard financial results. Traders should watch for upcoming catalysts: givastomig Phase 1b data at ESMO Oct 2026, Phase 3 initiation as early as YE 2026, and VIS-101 Phase 2b start in 2H 2026. The strong cash position reduces near-term dilution risk, but the stock's reaction will hinge on clinical data readouts and partnership announcements.
Price Chart
Executive Summary
NovaBridge Biosciences issued an investor presentation on August 20, 2026, highlighting its clinical pipeline, financial position, and strategic model. The presentation emphasizes strong Phase 1b data for lead candidate givastomig (77% ORR at 8 mg/kg in 1L GEA), a $5B+ peak sales potential across indications, and a debt-free balance sheet with ~$216M in cash and investments as of June 30, 2026. The filing is a routine corporate update with no new financial results or material definitive agreements, but it provides forward-looking catalysts and pipeline expansion details that are notable for a pre-revenue biotech.
Key Facts
- NovaBridge reported ~$216M in cash and investments as of June 30, 2026, with no debt.
- Givastomig showed 77% confirmed ORR at 8 mg/kg in Phase 1b first-line gastroesophageal adenocarcinoma.
- Management estimates $5B+ peak sales potential for givastomig across all indications, if approved.
- VIS-101 Phase 2b expected to start in 2H 2026 for neovascular AMD.
- Company has 3 clinical-stage assets and has screened over 700 assets.
- Signed term sheet for VIS-102, a potential best-in-class biologic for a rare disease.
- Partnership discussions in progress for givastomig, Visara, and Europe positioning.
Financial Impact
~$216M cash and investments; no debt; no revenue reported
Risk Factors
- Pre-revenue biotech with no approved products; all value depends on clinical trial success and regulatory approvals.
- Forward-looking statements are aspirational; actual results may differ materially.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-357817 |
| Document: nbp_-_6-k_for_corporate_.htm | 0001193125-26-357817 |
| Document: 0001193125-26-357817-index-headers.html | 0001193125-26-357817 |
| Document: 0001193125-26-357817-index.html | 0001193125-26-357817 |
| Document: 0001193125-26-357817.txt | 0001193125-26-357817 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $1.49 | awaiting T+5 | — | $1.22 (−18.46%) |
Oct 25, 2026 1d ago | Press Release | $1.42 | awaiting T+5 | — | $1.22 (−14.44%) |
Oct 23, 2026 3d ago | 6-K | $1.37 | awaiting T+5 | — | $1.22 (−11.31%) |
Oct 13, 2026 13d ago | 6-K | $1.29 $1.43 | ▲ +10.47% | ▲ +11.62% | $1.22 (−5.81%) |
Sep 8, 2026 6w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.22 (−31.74%) |
Sep 8, 2026 6w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.22 (−31.74%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.22 (+36.39%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▼ −1.05% | ▼ −2.16% | $1.22 (−36.39%) |
Aug 20, 2026 9w ago | Press Release | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.22 (+36.39%) |
Jul 24, 2026 13w ago | 6-K | $1.78 $1.60 | ▼ −10.11% | ▼ −11.19% | $1.22 (−31.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers